Estrella Immunopharma Inc. Common Stock (ESLA)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, honest accounting, and a margin of safety. Estrella Immunopharma is a clinical-stage biotech with no revenue and no profits. Its lead candidate EB103 is in Phase I/II for diffuse large B-cell lymphoma; EB104 and EB201 are still preclinical. That is a lottery ticket tied to scientific outcomes, not a franchise with pricing power. The filed figures show losses every period I can see. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$2.3 million, or -$0.05 per diluted share. In fiscal Q1 2026, ended 2026-03-31, it was also -$2.3 million and -$0.05. For FY2025, ended 2025-12-31, net loss was -$13.1 million, or -$0.35 per diluted share. FY2024 lost -$7.3 million, and FY2023 lost -$11.1 million. No revenue is reported. Free cash flow is -$9.4 million trailing twelve months; against a $13.7 million market cap, FairStock's FCF yield is -68.7%. FairStock's Piotroski score is 0/9 and Altman Z-score is -35.91, signs of extreme financial weakness. FairStock's ROCE is -251.86%. At the 2026-10-13 close of $0.31, FairStock's P/E is negative at -1.26. A stock near its 52-week low of $0.29 may look cheap, but there is no earnings or book value anchor here. The 52-week high was $3.15. The FairStock Score is 23/100. This is speculation on clinical trial results and future financing, not a Graham-style value investment. I would need evidence of cash runway, trial success, and a path to profitability before calling it anything other than a high-risk lottery ticket.

In plain English: Estrella Immunopharma is a medical research company working on new T-cell treatments for blood cancers and other diseases; its lead treatment is in early human testing. It has no revenue yet and has lost money every year, with the latest full-year loss at $13.1 million. At $0.31, the price is very low, but there is little current business profit or cash flow to support it, so the shares depend heavily on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-06-30) · FY2023 10-K (period ended 2023-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer